LT3061760T - Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai - Google Patents
Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliaiInfo
- Publication number
- LT3061760T LT3061760T LTEP15185548.3T LT15185548T LT3061760T LT 3061760 T LT3061760 T LT 3061760T LT 15185548 T LT15185548 T LT 15185548T LT 3061760 T LT3061760 T LT 3061760T
- Authority
- LT
- Lithuania
- Prior art keywords
- deuterated
- inhibitors
- monoamine transporter
- vesicular monoamine
- benzoquinolizine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
- C07D455/06—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9789608P | 2008-09-18 | 2008-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3061760T true LT3061760T (lt) | 2018-02-26 |
Family
ID=42107127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15185548.3T LT3061760T (lt) | 2008-09-18 | 2009-09-18 | Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai |
Country Status (20)
| Country | Link |
|---|---|
| US (16) | US8524733B2 (lt) |
| EP (4) | EP2610254B1 (lt) |
| JP (3) | JP5616345B2 (lt) |
| CN (2) | CN102186848B (lt) |
| AU (1) | AU2009303758B8 (lt) |
| BR (1) | BRPI0913457B8 (lt) |
| CA (2) | CA2736409C (lt) |
| CY (1) | CY1120060T1 (lt) |
| DK (2) | DK3061760T3 (lt) |
| ES (4) | ES2425623T3 (lt) |
| HR (1) | HRP20180239T1 (lt) |
| HU (1) | HUE038158T2 (lt) |
| LT (1) | LT3061760T (lt) |
| NO (1) | NO3061760T3 (lt) |
| NZ (1) | NZ591615A (lt) |
| PL (1) | PL3061760T3 (lt) |
| PT (1) | PT3061760T (lt) |
| SI (1) | SI3061760T1 (lt) |
| SM (1) | SMT201800067T1 (lt) |
| WO (1) | WO2010044981A2 (lt) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3061760T (lt) * | 2008-09-18 | 2018-02-26 | Auspex Pharmaceuticals, Inc. | Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai |
| CA2778886C (en) * | 2009-11-10 | 2014-01-07 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| US9572880B2 (en) | 2010-08-27 | 2017-02-21 | Sienna Biopharmaceuticals, Inc. | Ultrasound delivery of nanoparticles |
| ES2717543T3 (es) | 2010-08-27 | 2019-06-21 | Sienna Biopharmaceuticals Inc | Composiciones y métodos para la termomodulación dirigida |
| WO2012081031A1 (en) | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| NZ705372A (en) | 2012-09-18 | 2018-07-27 | Auspex Pharmaceuticals Inc | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| IL316627A (en) | 2012-10-11 | 2024-12-01 | Nanocomposix Inc | Silver nanoplate compositions and methods |
| MX2015009719A (es) | 2013-01-31 | 2016-08-08 | Auspex Pharmaceuticals Inc | Inhibidores benzoquinolona de vmat2. |
| EP3049087A4 (en) * | 2013-09-27 | 2017-05-24 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| EP3071565A4 (en) * | 2013-11-22 | 2017-08-02 | Auspex Pharmaceuticals, Inc. | Methods of treating abnormal muscular activity |
| WO2015077521A1 (en) * | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| KR102391134B1 (ko) | 2013-12-03 | 2022-04-28 | 오스펙스 파마슈티칼스, 인코포레이티드 | 벤조퀴놀린 화합물을 제조하는 방법 |
| MX2016009817A (es) | 2014-01-27 | 2017-02-28 | Auspex Pharmaceuticals Inc | Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2. |
| US9782398B2 (en) * | 2014-02-07 | 2017-10-10 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof |
| EA201691582A1 (ru) * | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
| CN112741835A (zh) | 2014-05-06 | 2021-05-04 | 纽罗克里生物科学有限公司 | 用于运动机能亢进性运动障碍的治疗的vmat2抑制剂 |
| MA41557A (fr) * | 2015-02-18 | 2017-12-26 | Auspex Pharmaceuticals Inc | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 |
| DK3265085T3 (da) * | 2015-03-06 | 2022-10-03 | Auspex Pharmaceuticals Inc | Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser |
| US20180071024A1 (en) * | 2015-03-20 | 2018-03-15 | Sienna Biopharmaceuticals, Inc. | Enhanced efficacy and targeted topical delivery of drugs to skin with nanoparticles |
| MA56137B1 (fr) | 2015-10-30 | 2024-03-29 | Neurocrine Biosciences Inc | Sels de dihydrochlorure de valbénazine et leurs polymorphes |
| CA3009169A1 (en) | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| US10479787B2 (en) | 2016-04-22 | 2019-11-19 | Lupin Limited | Process for preparation of tetrabenazine and deutetrabenazine |
| WO2017221169A1 (en) | 2016-06-24 | 2017-12-28 | Lupin Limited | Premixes of deutetrabenazine |
| CN107936008B (zh) * | 2016-10-13 | 2022-06-14 | 泰州华元医药科技有限公司 | 氘代化合物及其医药用途 |
| TW201827051A (zh) | 2016-12-02 | 2018-08-01 | 美商神經性分泌生物科學公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| WO2018130345A1 (en) | 2017-01-10 | 2018-07-19 | Sandoz Ag | Crystalline valbenazine free base |
| MY203491A (en) | 2017-01-27 | 2024-06-30 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| US10954235B2 (en) | 2017-02-27 | 2021-03-23 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| KR20200003791A (ko) * | 2017-03-15 | 2020-01-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진의 유사체, 이의 제조 및 용도 |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| PL3684333T3 (pl) | 2017-09-21 | 2025-06-23 | Neurocrine Biosciences, Inc. | Formulacja walbenazyny o wysokiej dawce oraz kompozycje, sposoby i zestawy z nią związane |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| KR20250110361A (ko) | 2017-10-10 | 2025-07-18 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| US10786495B2 (en) * | 2017-10-10 | 2020-09-29 | The Regents Of The University Of California | Vesicular monoamine transporter 2 inhibitors for treating stuttering |
| WO2019130252A2 (en) | 2017-12-29 | 2019-07-04 | Mylan Laboratories Ltd | Methods and intermediates for preparing deutetrabenazine |
| US11806326B2 (en) | 2018-01-29 | 2023-11-07 | Jonathan Sackner-Bernstein | Methods for dopamine modulation in human neurologic diseases |
| US11505549B2 (en) * | 2018-02-01 | 2022-11-22 | Lakshmi Prasad ALAPARTHI | Process for preparation of Deutetrabenazine |
| WO2019166962A1 (en) | 2018-03-01 | 2019-09-06 | Mylan Laboratories Ltd | Deutetrabenazine polymorphs and methods for their preparation |
| IL278185B2 (en) * | 2018-04-25 | 2024-11-01 | Shinkei Therapeutics Inc | Tetrabenazine transdermal delivery device |
| US10632107B2 (en) | 2018-05-14 | 2020-04-28 | Apotex Inc. | Crystalline forms of benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| CN108794337A (zh) * | 2018-07-10 | 2018-11-13 | 上海华堇生物技术有限责任公司 | 一种3,4-二羟基-β-硝基苯乙烯的新制备方法 |
| MX2021001017A (es) | 2018-08-15 | 2021-04-19 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2). |
| AU2019362389B2 (en) | 2018-10-18 | 2024-12-12 | Oncopeptides Innovation Ab | Compounds containing deuterium |
| SG11202106344SA (en) | 2018-12-13 | 2021-07-29 | Auspex Pharmaceuticals Inc | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| EP4364738A3 (en) | 2020-06-10 | 2024-06-19 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| WO2022061058A1 (en) | 2020-09-17 | 2022-03-24 | Auspex Pharmaceuticals, Inc. | Multiparticulate dosage forms comprising deutetrabenazine |
| KR20230088399A (ko) | 2020-10-12 | 2023-06-19 | 오스펙스 파마슈티칼스, 인코포레이티드 | 듀테트라베나진을 포함하는 위체류성 제형 |
| RS67052B1 (sr) | 2021-03-22 | 2025-08-29 | Neurocrine Biosciences Inc | Vmat2 inhibitori i postupci primene |
| WO2023278987A1 (en) | 2021-06-30 | 2023-01-05 | Neurocrine Biosciences, Inc. | Valbenazine for use in the add-on treatment of schizophrenia |
| IL311249A (en) | 2021-09-17 | 2024-05-01 | Auspex Pharmaceuticals Inc | Multiparticulate dosage forms comprising deutetrabenazine |
| CA3245030A1 (en) | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences Inc | VALBENAZINE, A VMAT2 INHIBITOR, AS A FREE BASE OF A TOSYLATE OR DITOSYLATE SALT, INTENDED FOR USE IN THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE |
| IL317235A (en) | 2022-06-08 | 2025-01-01 | Auspex Pharmaceuticals Inc | Osmotic dosage forms comprising ditetrabenzene and methods of using the same |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| TW202521119A (zh) | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830993A (en) * | 1958-04-15 | Quinolizine derivatives | ||
| US3045021A (en) | 1959-09-24 | 1962-07-17 | Hoffmann La Roche | Preparation of substituted 2-oxobenzoquinolizines |
| DE1253271B (de) * | 1961-03-28 | 1967-11-02 | Mta | Verfahren zur Herstellung von 2-Oxo-1, 2, 3, 4, 6, 7-hexahydro-11bH-benzo[a]chinolizinen |
| US4316897A (en) * | 1980-09-10 | 1982-02-23 | Hoffmann-La Roche Inc. | Method of lowering serum prolactin |
| AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| ES2193921T3 (es) * | 1999-12-03 | 2003-11-16 | Pfizer Prod Inc | Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos. |
| EP1134290A3 (en) * | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US20080026081A1 (en) * | 2003-11-21 | 2008-01-31 | Axel Unterbeck | Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| EP1856135B1 (en) | 2005-01-19 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| KR101429302B1 (ko) | 2006-05-02 | 2014-08-11 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 방사성 표지된 디히드로테트라베나진 유도체 및 조영제로서의 이의 용도 |
| BRPI0718247B1 (pt) | 2006-11-08 | 2021-09-21 | Neurocrine Biosciences, Inc. | Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos |
| JP5264759B2 (ja) | 2006-11-21 | 2013-08-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ２，４−ピリミジンジアミン化合物のプロドラッグ塩およびそれらの使用 |
| US20100204258A1 (en) * | 2007-03-12 | 2010-08-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for modulating insulin secretion and glucose metabolism |
| US8008500B2 (en) * | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| US9827210B2 (en) * | 2007-06-29 | 2017-11-28 | Phovitreal Pty Ltd | Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration |
| WO2009124357A1 (en) | 2008-04-10 | 2009-10-15 | Malvin Leonard Eutick | Fast dissolving oral formulations for critical drugs |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| WO2011019956A2 (en) | 2009-08-12 | 2011-02-17 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| LT3061760T (lt) * | 2008-09-18 | 2018-02-26 | Auspex Pharmaceuticals, Inc. | Deuterinti benzochinolizino dariniai kaip vezikuliarinio monoamino transporterio 2 slopikliai |
| US20100113496A1 (en) * | 2008-09-25 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of vmat2 |
| EP2539347A2 (en) | 2010-02-24 | 2013-01-02 | Auspex Pharmaceuticals, Inc. | Trimethoxyphenyl inhibitors of tyrosine kinase |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
-
2009
- 2009-09-18 LT LTEP15185548.3T patent/LT3061760T/lt unknown
- 2009-09-18 HU HUE15185548A patent/HUE038158T2/hu unknown
- 2009-09-18 CA CA2736409A patent/CA2736409C/en active Active
- 2009-09-18 ES ES09820972T patent/ES2425623T3/es active Active
- 2009-09-18 EP EP13160950.5A patent/EP2610254B1/en not_active Not-in-force
- 2009-09-18 PL PL15185548T patent/PL3061760T3/pl unknown
- 2009-09-18 AU AU2009303758A patent/AU2009303758B8/en active Active
- 2009-09-18 SI SI200931797T patent/SI3061760T1/en unknown
- 2009-09-18 SM SM20180067T patent/SMT201800067T1/it unknown
- 2009-09-18 ES ES13160950.5T patent/ES2563820T3/es active Active
- 2009-09-18 EP EP15185548.3A patent/EP3061760B1/en active Active
- 2009-09-18 DK DK15185548.3T patent/DK3061760T3/en active
- 2009-09-18 NO NO15185548A patent/NO3061760T3/no unknown
- 2009-09-18 US US12/562,621 patent/US8524733B2/en active Active
- 2009-09-18 DK DK09820972.9T patent/DK2326643T3/da active
- 2009-09-18 WO PCT/US2009/057480 patent/WO2010044981A2/en not_active Ceased
- 2009-09-18 CN CN200980141378.0A patent/CN102186848B/zh active Active
- 2009-09-18 CA CA2972242A patent/CA2972242A1/en not_active Abandoned
- 2009-09-18 CN CN201410524867.7A patent/CN104311552A/zh active Pending
- 2009-09-18 NZ NZ591615A patent/NZ591615A/en unknown
- 2009-09-18 BR BRPI0913457A patent/BRPI0913457B8/pt active IP Right Grant
- 2009-09-18 PT PT151855483T patent/PT3061760T/pt unknown
- 2009-09-18 EP EP17199778.6A patent/EP3345905B1/en active Active
- 2009-09-18 ES ES15185548.3T patent/ES2652289T3/es active Active
- 2009-09-18 JP JP2011527995A patent/JP5616345B2/ja active Active
- 2009-09-18 ES ES17199778T patent/ES2896678T3/es active Active
- 2009-09-18 EP EP09820972.9A patent/EP2326643B1/en active Active
-
2013
- 2013-07-03 US US13/934,960 patent/US20130296360A1/en not_active Abandoned
-
2014
- 2014-03-25 US US14/224,883 patent/US20140206712A1/en not_active Abandoned
- 2014-03-25 US US14/225,010 patent/US20140206713A1/en not_active Abandoned
- 2014-08-08 US US14/454,911 patent/US20140350044A1/en not_active Abandoned
- 2014-09-11 JP JP2014185634A patent/JP5970037B2/ja active Active
- 2014-10-15 US US14/515,047 patent/US20150080427A1/en not_active Abandoned
-
2015
- 2015-07-23 US US14/807,364 patent/US20150328207A1/en not_active Abandoned
-
2016
- 2016-02-11 US US15/041,571 patent/US20160158220A1/en not_active Abandoned
- 2016-04-08 US US15/094,517 patent/US20160220558A1/en not_active Abandoned
- 2016-07-08 JP JP2016136178A patent/JP6138322B2/ja active Active
- 2016-09-01 US US15/254,912 patent/US20160367548A1/en not_active Abandoned
- 2016-09-06 US US15/257,372 patent/US20160375005A1/en not_active Abandoned
-
2017
- 2017-02-28 US US15/445,402 patent/US20170166562A1/en not_active Abandoned
-
2018
- 2018-02-07 HR HRP20180239TT patent/HRP20180239T1/hr unknown
- 2018-02-07 CY CY20181100152T patent/CY1120060T1/el unknown
- 2018-12-05 US US16/210,077 patent/US20190375746A1/en not_active Abandoned
-
2020
- 2020-03-17 US US16/821,067 patent/US20200347048A1/en not_active Abandoned
-
2021
- 2021-11-05 US US17/519,922 patent/US20220267317A1/en not_active Abandoned
-
2025
- 2025-03-17 US US19/081,808 patent/US20250326747A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3061760T3 (pl) | Deuterowane pochodne benzochinoliny jako inhibitory pęcherzykowego transportera monoamin 2 | |
| HRP20180662T1 (hr) | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze | |
| TWI347321B (en) | Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| SI2178840T1 (sl) | Derivativi azabifenilaminobenzojske kisline kot dhodh inhibitorji | |
| IL200617A0 (en) | Substituted pyrimidodiazepines useful as plk1 inhibitors | |
| ZA200807263B (en) | Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors | |
| PT2094263E (pt) | Derivados da 2-adamantil-butiramida como inibidores seletivos da 11-beta-hsd1 | |
| IL192603A0 (en) | Thieno-pyridine derivatives as mek inhibitors | |
| IL210990A0 (en) | Piperidine derivatives as jak3 inhibitors | |
| DK2010496T3 (da) | 4-anilinoquinolin-3-carbonsyreamider som CSF-1R-kinaseinhibitorer | |
| SI2225238T1 (sl) | Derivati amidov 6,7-dihidro-5H-imidazo(1,2-a)imidazol-3-karboksilne kisline | |
| ZA200908612B (en) | 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase | |
| ZA200807074B (en) | 4-phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
| IL208626A0 (en) | Imidazolidinone derivatives as 11b-hsd1 inhibitors | |
| IL196000A0 (en) | 2-arylindole derivatives as npges-i inhibitors | |
| ZA200808598B (en) | Pyrrolopyrimidine derivatives used as HSP90 inhibitors | |
| ZA201000383B (en) | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors |